

Table 1 - Baseline clinical characteristics of patients with advanced stage nLPHL

	N (%)
Age in years, median (range)	14 (4 – 18)
Country	
UK	19 (46.3)
FR	22 (53.7)
Sex	
Male	34 (82.9)
Female	7 (17.1)
Stage at diagnosis	
II	2 (4.9)
III	33 (80.5)
IV	6 (14.6)
Sites	
Mediastinum	12 (29.3)
Axillary	14 (34.2)
Para-aortic	9 (22.0)
Inguinal	12 (29.3)
Coeliac	4 (9.8)
Spleen	9 (22.0)
Iliac	10 (24.4)
Bone	3 (7.3)
Subclavian	3 (7.3)
Hepatic hilum	2 (4.9)
Mesenteric	3 (7.3)
Other*	11 (26.8)

*All sites appearing only once: caval, hepatic, sub-pectoral, pulmonary parenchyma, brachial plexus, mesenteric, medullary, epitrochlear, chest (posterior to R hilum), groin, pectoral, perisplenic, portal, pelvis, abdomen and supraclavicular

Table 2 - First line chemotherapy regimens

Therapy	Total N (%)	Including R* N (%)	Including IFRT
Chemotherapy	38 (92.7)	13 (31.7)	6 (14.6)
CVP	5 (12.2)	2 (4.9) ¹	1 (2.4)
ABVD/ChLVPP	7 [17.1]	0	0
OEPA COPDAC	5 (12.2)	0	2 (4.9)
OEPA/COPP	5 (12.)	1 (2.4)	0
ABVD	3 (7.3)	3 (7.3)	0
CHOP	5 (12.2)	5 (12.2)	0
VPVB	1 (2.4)	0	0
COPPABV	1 (2.4)	0	0
COP + LMT96 (MACAO)	1 (2.4)	0	0
MOPP + ABVP	3 (7.3)	0	3 (7.3)
OEPA + ABVD + R-IEP	1 (2.4)	1 (2.4)	0
COPP + R-COPDAM + R-CYM	1 (2.4)	1 (2.4)	0
Surgery only	2 (4.9)	-	-
Rituximab only	1 (2.4)	1 (2.4)	-

¹One patient had chemotherapy, rituximab and involved field radiotherapy

* Rituximab

See appendix 1 for expansion of chemotherapy regimen acronyms

Table 3 - Treatment at relapse

Therapy	Total N (%)	Including R* N (%)	Including IFRT N (%)
Chemotherapy	3 (37.5)	2 (25.0)	2 (25.0)
4 R-ABVD	2 (25.0)	2 (25.0)	2 (25.0)
IEP x 2, ABVD x 1, ESHAP x 4	1 (12.5)	0	0
Rituximab only	4 (50.0)	4 (50.0)	-
Auto HSCT	1 (12.5)	-	1 (12.5)

* Rituximab

Table 4 – Characteristics and first line treatment of the patients who relapsed.

	No relapse N (%)	Relapse N (%)
Baseline characteristics		
Age in years, median (range)	14 (5-18)	12.5 (4 – 17)
Sex		
Male	26 (76.5)	8 (23.5)
Female	7 (100.0)	0
Stage at diagnosis		
II	1 (50.0)	1 (50.0)
III	27 (81.8)	6 (18.2)
IV	5 (83.3)	1 (16.5)
B symptoms		
Absent	30 (88.2)	4 (11.8)
Present	2 (33.3)	4 (66.7)
Unknown	1	0
Splenic disease		
Absent	25 (78.1)	7 (21.9)
Present	8 (89.9)	1 (11.1)
Variant histology		
Absent	8 (88.9)	1 (11.1)
Present	1 (100)	0
Not assessed	24	7
Initial treatment type		
Chemotherapy alone	17 (85.0)	3 (15.0)
R-Chemotherapy	11 (91.7)	1 (8.3)
Chemotherapy + RT	2 (40.0)	3 (60.0)
R-Chemotherapy + RT	1 (100)	0
R only	0	1 (100)
Surgery only	2 (100)	0

Figure 1 - First line treatment


	First line treatment	Response	Second line treatment	Response	Status
Chemotherapy only group (N=20)	ABVDx3; ChLVPPx3 (N=7)	CR (N=20)	Alive and in CR (N=7)		Alive and in CR (N=20)
	OEPA/COPP (N=4)		IEP x 2, ABVD x 1, ESHAP x 4	CR	
	CVP (N=3)		Alive and in CR (N=5)		
	OEPA COPDAC (N=3)		2 IEP + 2 ABVD + BEAM + AUTOGRAFT + RT20 Gy	CR	
	COP + LMT96 (MACAO) (N=1)		4 R-ABVD + RT 20Gy	CR	
	COPPABV (N=1)		Alive and in CR (N=5)		
	VBVP (N=1)				

	First line treatment	Response	Second line treatment	Response	Status
Chemotherapy + R Group (N=12)	R-CHOP (N=5)	CR (N=12)	Alive and in CR (N=9)		Died (N=1, Ewing's sarcoma)
	R-ABVD (N=3)				Alive and in CR/CRu (N=11)
	R-CVP (N=1)				
	R-OEPA/COPP (N=1)		Rituximab	CR	
	OEPA + R-ABVD + R-IEP (N=1)		Alive and in CR (N=2)		
	COPP + R-COPDAM + R-CYM + R (N=1)				

	First line treatment	Response	Second line treatment	Response	Third line treatment	Status
Chemotherapy + RT (N=5)	MOPP + ABVP + RT (N=3)	CR (N=5)	Rituximab	CR (N=3)	6x R-CHOP+ BEAM autograft	Alive and in CR/CRu (N=5)
	OEPA COPDAC + RT (N=2)		Alive and in CR (N=2)		4xR-ABVD+ BEAM autograft	
					Alive and in CR (N=3)	

	First line treatment	Response	Second line treatment	Response	Status
Other treatments (N=4)	Surgery only (N=2)	CR (N=4)	Alive and in CR (N=2)		Alive and in CR/CRu (N=4)
	R only (N=1)		R-ABVD + RT 20 Gy	CR	
	R-Chemo + RT: R-CVP + RT (N=1)		Alive and in CR (N=2)		

Figure 2 - Progression free survival



Appendix 1

OEPA - Vincristine, Etoposide, Prednisolone, Doxorubicin

COPP - Cyclophosphamide, Vincristine, Prednisolone, Procarbazine

R-OEPA/COPP - Rituximab plus OEPA and COPP

COPPABV - Cyclophosphamide, Vincristine, Prednisolone, Procarbazine, Doxorubicin, Bleomycin, Vinblastine,

COPDAC - Cyclophosphamide, Vincristine, Prednisolone, Dacarbazine,

ABVD - Doxorubicin, Bleomycin, Vinblastine, Dacarbazine

ABVP - Doxorubicin, Bleomycin, Vinblastine, Prednisolone

R-ABVD - Rituximab plus ABVD

ChIVPP - Chlorambucil, Vinblastine, Prednisolone, Procarbazine

MOPP - Mustine, Vincristine, Prednisolone, Procarbazine

CHOP - Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone

R-CHOP - Rituximab plus CHOP

COP - Cyclophosphamide, Vincristine, Prednisolone

CVP - Cyclophosphamide, Vinblastine, Prednisolone

R-CVP - Rituximab plus CVP

COPADM - Cyclophosphamide, Vincristine, Prednisolone Doxorubicin, Methotrexate

R-COPADM - Rituximab plus COPADM

CYM - Cytarabine, Methotrexate

R-IEP - Rituximab, Iphosfamide, Etoposide, Cisplatin

VBVP - Etoposide, Bleomycin, Vinblastine, Prednisolone

BEAM - Carmustine, Etoposide, Cytarabine, Melphalan

ESHAP - Etoposide, Methylprednisolone, Cytarabine and Cisplatin

